Multi-omics integration in deciphering non-small cell lung cancer drug resistance: current status, challenges, and future prospects.

Lung cancer is the leading cause of cancer-related deaths globally. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases, and drug resistance severely undermines treatment efficacy. This review summarizes recent advances in elucidating NSCLC drug-resistance mechanisms using multi-omics integration. Multi-omics integration systematically reveals the molecular networks of drug resistance, identifies key biomarkers and targets, and facilitates the screening of high-priority candidates for drug development through experimental validation. Small-molecule inhibitors targeting drug-resistant proteins and multi-omics-guided combination therapies offer strategies to reverse resistance. Future directions involve developing simultaneous multi-omics detection technologies, leveraging artificial intelligence for intelligent data analysis, establishing standardized frameworks for data sharing, and implementing personalized medicine based on multi-omics to improve patient prognosis.